Halozyme Therapeutics, Inc.
HALO · Nasdaq · United States · Health Care · Pharma / Biotech / Life Sci
- Coverage
- FY2016–FY2025
- History
- 10 years
- Latest filing
- 10-K · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Feb 2026
Headline figures
Halozyme Therapeutics, Inc. at a glance
In FY2025, Halozyme Therapeutics, Inc. reported revenue of USD 1,396,611 thousands, EBITDA of USD 890,644 thousands, EBITDA margin of 63.8%.
| USD thousands | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 1,015,324 | 1,396,611 | |||
| EBITDA | 632,787 | 890,644 | |||
| EBITDA margin | 62.3% | 63.8% | |||
| Free cash flow | 468,368 | 644,588 | |||
| ROIC | 30.7% | 30.5% |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas